Overview

Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
To assess the safety and the preliminary efficacy data on the three doses of the new Cosmo Technologies oral rifamycin SV colon-release 200 mg tablets manufactured according to MMX technology (CB-01-11) in the treatment of infectious diarrhoea.
Phase:
Phase 2
Details
Lead Sponsor:
Cosmo Technologies Ltd
Treatments:
Rifamycin SV
Rifamycins